As a component of a contract with the Biomedical Advanced Development Authority (BARDA), a federal agency supporting development of medical countermeasures to terrorist threats, a type B meeting was held with the FDA in February 2015. Guidance obtained from the FDA meeting was useful in determining the next steps for Countervail to take with product development activities related to the application of AverTox as a neuroprotectant against the neurological damage that occurs from exposure to sub-lethal levels of nerve agent.